Human LR3IGF-I is more potent than IGF-I in vitro ａnd in vivo. This increased potency is due to reduced binding of LR3IGF-I to most of the IGF binding proteins which modify the biological actions of IGF-I.

Human LR3IGF-I binds to the type 1 IGF receptor with similar affinity to wild type IGF-I.LR3

IGF-I was developed by GroPep specifically for supplementation of mammalian cell culture to support the survival ａnd proliferation of cells. It is engineered to have a higher biological potency than native IGF-I or IGF-II ａnd has several advantages over recombinant insulin. Supplementation of cell cultures with LR3IGF-I at a much lower concentration results in equivalent or better productivity than supplementation with standard concentrations of insulin. LR3IGF-I is better able to stimulate the type I IGF receptor ａnd thus induce a higher level of activation of intracellular signalling molecules which are responsible for promoting cell survival by inhibition of apoptosis.

Media grade LR3IGF-I is a high quality product for use in commercial cell culture.It can also be used as a research reagent at an economical cost to enable studies where higher quantities of peptide are required.

References Francis GL et al (1992) Journal of Molecular Endocrinology 8, 213-223

Yandell C et al (2004) Bioprocess International 2, 56-64

Source: Produced in E.coli.

Molecular Weight: 9110.6 ± 2 Daltons

Purity: ≥ 95 % (by SDS gel electrophoresis)

HPLC analysis: Three peaks with main peak being > 50% of total area

(Other species are micro heterogeneous forms which have biological activity)

N-terminal sequence: Analysis of 18 residues

Biological Activity: Proliferation of Chinese Hamster Ovary (CHO) cells

(EC50 ≤ 10 ng/ml)

Endotoxin: ≤ 0.1 EU/µg

Appearance: White powder freeze-dried from 0.1M acetic acid ａnd stored under

nitrogen at a slight vacuum.

Storage/Stability: At least 2 years at 2-8°C (as a freeze dried product).

Reconstitution: Handling of GroPep IGF-I, IGF-II ａnd IGF analogues

艾美捷LR3胰島素樣生長因子-I#GRO-AM001是IGF-I的83個氨基酸的類似物，其包含在位置3用精氨酸取代谷氨酰胺的完整人IGF-I序列，加上在N-末端的13個氨基酸的延伸肽。

人類LR3 IGF-I在體外和體內(nèi)都比IGF-I更有效。這種效力的提高是由于LR3的結(jié)合IGF-I與大多數(shù)改變IGF-I生物作用的IGF結(jié)合蛋白結(jié)合。

人類LR3 IGF-I以與野生型IGF-I相似的親和力與1型IGF受體結(jié)合。LR3型IGF-I由GroPep開發(fā)，門用于補充哺乳動物細胞培養(yǎng)物支持細胞的存活和增殖。它被設(shè)計成具有比天然IGF-I或IGF-II，并且與重組胰島素相比具有幾個優(yōu)點。細胞的補充含有LR3的培養(yǎng)物IGF-I在低得多的濃度下產(chǎn)生與補充標準濃度的胰島素。LR3型IGF-I能夠更好地刺激I IGF受體，從而誘導更高水平的細胞內(nèi)信號分子激活負責通過抑制細胞凋亡來促進細胞存活。

LR3胰島素樣生長因子-I詳細信息：

來源：產(chǎn)自大腸桿菌。

分子量：9110.6±2道爾頓

純度：≥95%（SDS凝膠電泳）

HPLC分析：三個峰，主峰面積大于總面積的50%

（其他物種是具有生物活性的微異質(zhì)形式）

N端序列：18個殘基的分析

生物活性：中國倉鼠卵巢（CHO）細胞的增殖

（EC50≤10 ng/ml）

內(nèi)毒素：≤0.1 EU/µg

外觀：從0.1M乙酸中冷凍干燥的白色粉末，在

在輕微真空下的氮氣。

儲存/穩(wěn)定性：在2-8°C下至少保存2年（作為冷凍干燥產(chǎn)品）。

重組：GroPep IGF-I、IGF-II和IGF類似物的處理

LR3胰島素樣生長因子-I相關(guān)研究：

人LR3IGF-I（受體）

人[Arg3]IGF-I（介質(zhì)）

人LR3IGF-I ELISA

人IGF-I（介質(zhì)）

文獻參考：

Francis GL et al (1992) Journal of Molecular Endocrinology 8, 213-223 Yandell C et al (2004) Bioprocess International 2, 56-64  

來源：https://www.amyjet.com/featured/mtdna-target.shtml